{"entity":{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","aka":["Impact Therapeutics, Inc.","IMPACT Therapeutics (Shanghai)"],"tldr":"IMPACT is a Shanghai biotech built around DNA damage response drugs; its PARP inhibitor senaparib met its phase 3 endpoint as maintenance in ovarian cancer and is approved in China.","summary":"IMPACT Therapeutics, headquartered in Shanghai, develops inhibitors of the DNA damage response. Its PARP inhibitor senaparib (IMP4297) improved progression-free survival as first-line maintenance in advanced ovarian cancer in the phase 3 FLAMES trial and gained Chinese approval, and its Wee1 and ATR inhibitors follow in earlier trials. Its trials are registered on ClinicalTrials.gov under IMPACT as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.impacttherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Impact Therapeutics, Inc.","url":"https://clinicaltrials.gov/search?lead=Impact%20Therapeutics%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140046067"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["imp4927"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05269316","nct06907043"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.impacttherapeutics.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/impact-therapeutics/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/"},{"id":"nct04169997","kind":"trial","name":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","route":"/trials/nct04169997/"},{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/"},{"id":"nct05269316","kind":"trial","name":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","route":"/trials/nct05269316/"}]}}